In one paragraphArticle in Microbiology spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
17 authors.
Bradley WardUCLouvain [Bruxelles-Woluwe], Louvain Drug Research Institute (LDRI), Integrated Pharmacometrics, Pharmacogenomics and Pharmacokinetics Group (PMGK), Woluwe-Saint-Lambert, Belgium.ORCID 0000-0003-0778-0153 Laure B BindelsUCLouvain [Bruxelles-Woluwe], Louvain Drug Research Institute (LDRI), Metabolism and Nutrition Research Group (MNUT), Woluwe-Saint-Lambert, Belgium.
Jean-Luc BalligandWELBIO (Walloon Excellence in Life Sciences and Biotechnology), WELBIO Department, WEL Research Institute, Wavre, Belgium.ORCID 0000-0002-0522-4156 Bertrand BearzattoInstitut de Recherche Experimentale et Clinique (IREC), Centre for Applied Molecular Technologies (CTMA), UCLouvain, Woluwe-Saint-Lambert, Belgium.ORCID 0000-0001-5193-6819 Guido BommerDe Duve Institute, MASSPROT, UCLouvain, Woluwe-Saint-Lambert, Belgium.
Patrice D CaniUCLouvain [Bruxelles-Woluwe], Louvain Drug Research Institute (LDRI), Metabolism and Nutrition Research Group (MNUT), Woluwe-Saint-Lambert, Belgium.ORCID 0000-0003-2040-2448 Julien De GreefUCLouvain [Bruxelles-Woluwe], Institut de Recherche Expérimentale et Clinique (IREC), Louvain Center for Toxicology and Applied Pharmacology (LTAP), Woluwe-Saint-Lambert, Belgium.ORCID 0000-0003-0200-1237 Joseph P DewulfUCLouvain [Bruxelles-Woluwe], Institut de Recherche Expérimentale et Clinique (IREC), Louvain Center for Toxicology and Applied Pharmacology (LTAP), Woluwe-Saint-Lambert, Belgium.
Laurent GattoUCLouvain [Bruxelles-Woluwe], de Duve Institute (DDUV), Computational Biology and Bioinformatics Unit (CBIO), Woluwe-Saint-Lambert, Belgium.
Vincent HaufroidUCLouvain [Bruxelles-Woluwe], Institut de Recherche Expérimentale et Clinique (IREC), Louvain Center for Toxicology and Applied Pharmacology (LTAP), Woluwe-Saint-Lambert, Belgium.ORCID 0000-0001-5040-9806 Sébastien JodogneUCLouvain [Louvain-La-Neuve], Institute of Information and Communication Technologies, Electronics and Applied Mathematics (ICTEAM), Computer Science and Engineering Department (INGI), Louvain-la-Neuve, Belgium.ORCID 0000-0001-6685-7398 Benoît KabambaUCLouvain [Bruxelles-Woluwe], Institut de Recherche Experimentale et Clinique (IREC), Woluwe-Saint-Lambert, Belgium.
Sébastien Pyr Dit RuysUCLouvain [Bruxelles-Woluwe], Institut de Recherche Expérimentale et Clinique (IREC), Louvain Center for Toxicology and Applied Pharmacology (LTAP), Woluwe-Saint-Lambert, Belgium.
Didier VertommenDe Duve Institute, MASSPROT, UCLouvain, Woluwe-Saint-Lambert, Belgium.
Jean Cyr YombiUCLouvain [Bruxelles-Woluwe], Institut de Recherche Experimentale et Clinique (IREC), Woluwe-Saint-Lambert, Belgium.ORCID 0000-0001-8424-2346 Leïla Belkhir *UCLouvain [Bruxelles-Woluwe], Institut de Recherche Expérimentale et Clinique (IREC), Louvain Center for Toxicology and Applied Pharmacology (LTAP), Woluwe-Saint-Lambert, Belgium.ORCID 0000-0002-1701-7584 Laure Elens *UCLouvain [Bruxelles-Woluwe], Louvain Drug Research Institute (LDRI), Integrated Pharmacometrics, Pharmacogenomics and Pharmacokinetics Group (PMGK), Woluwe-Saint-Lambert, Belgium.ORCID 0000-0002-0039-3583 Funding
Fondation Saint Luc 2021-I4201010-221801Fondation Saint Luc FRCFonds De La Recherche Scientifique - FNRS EOS 40007505Fonds De La Recherche Scientifique - FNRS HC01020FFonds Spéciaux de Recherche 2021Fonds Spéciaux de Recherche ARC 25/30-151Walloon excellence in life sciences and biotechnology WELBIO-CR-2022A-02P
6 · The paper itselfAbstract
This longitudinal study investigated the differential composition of the nasopharyngeal microbiome in patients presenting different COVID-19 infectious phenotypes and its evolution during convalescence, with a focus on post-acute sequelae of SARS-CoV-2 (PASC) and its potential microbiome-related mechanisms. Microbiota composition was assessed for a cohort of healthy participants (
Indexed as
ActinobacteriaCorynebacteriumCOVID-19NasopharynxPost-Acute COVID-19 SyndromeAdultFemaleHumansLongitudinal StudiesMaleMicrobiotaMiddle AgedSARS-CoV-2CorynebacteriumCOVID-19Dolisigranum pigrumpost-acute sequelae of COVID19respiratory microbiome
Identifiers
PMID41841761
PMCPMC13055391
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390